Pulmonary fibroblasts-secreted CXCL10 polarizes alveolar macrophages under pro-inflammatory stimuli

Background: During acute lung injury, lung fibroblasts produce chemokines that assist the activation and migration of resident macrophages. The interactions between pulmonary fibroblasts and alveolar macrophages demonstrate the early event in the recruitment of immune cells, and the production of chemokines appear to be central mediators of the initiation and progression of inflammatory responses. In this study, the aim was to investigate the signaling pathway leading to CXCL10 secretion and the effects of CXCL10 released by activated fibroblasts on regulating macrophage polarization in a pro-inflammatory microenvironment. Methods: The expression of chemokines CCL2, CCL5, CXCL10, and CXCL12, and the phosphorylation of signaling molecules STAT3, FAK, GSK3 alpha beta and PKC delta were investigated by real time-PCR, ELISA, or Western blot on TNF alpha- or IL-1 beta-activated MRC-5 pulmonary fibroblasts. By collecting conditioned medium from TNF alpha-activated fibroblasts, the expression of iNOS and arginase I on MH-S alveolar macrophages were examined by real-time PCR. Surface markers CD86 and CD206 expressions on alveolar macrophages were also evaluated by flow cytometry. Results: We found that CXCL10 production was significantly elevated on MRC-5 fibroblasts under TNF-alpha or IL-1 beta treatment. In addition, we revealed that TNF alpha and IL-1 beta initiated phosphorylation of STAT3, FAK, GSK3 alpha beta and PKC delta signaling cascade, leading to the elevation of CXCL10 expression. Moreover, conditioned medium collected from TNF alpha-activated MRC-5 fibroblasts increased iNOS and CD86 expressions and decreased arginase I and CD206 expressions on MH-S alveolar macrophages, and neutralization of CXCL10 abolished these observed phenomena. Conclusion.: These results suggest that CXCL10 is crucial in activated fibroblasts-promoted M1 phenotype polarization of alveolar macrophages. In this regard, targeting fibroblasts-released CXCL10 may be promising as anti-inflammatory therapy against acute lung injury.